dc.contributor.author | Mangia, A | en_US |
dc.contributor.author | Foster, GR | en_US |
dc.contributor.author | Berg, CP | en_US |
dc.contributor.author | Curescu, M | en_US |
dc.contributor.author | Ledinghen, VD | en_US |
dc.contributor.author | Habersetzer, F | en_US |
dc.contributor.author | Manolakopoulos, S | en_US |
dc.contributor.author | Negri, E | en_US |
dc.contributor.author | Papatheodoridis, G | en_US |
dc.contributor.author | Ahlers, S | en_US |
dc.contributor.author | Castillo, M | en_US |
dc.contributor.author | Bakalos, G | en_US |
dc.contributor.author | Mauss, S | en_US |
dc.contributor.author | PegBase Group Investigators | en_US |
dc.date.accessioned | 2017-06-07T11:10:13Z | |
dc.date.available | 2017-02-19 | en_US |
dc.date.issued | 2017 | en_US |
dc.date.submitted | 2017-05-10T10:12:42.661Z | |
dc.identifier.issn | 1108-7471 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/23615 | |
dc.description.abstract | BACKGROUND: The aim of the study was to determine the efficacy and safety of triple therapy with a first-generation protease inhibitor (PI; boceprevir, telaprevir) plus peginterferon alfa-2a or -2b plus ribavirin, and dual therapy (peginterferon alfa-2a or -2b plus ribavirin) in patients with chronic hepatitis C (CHC) in routine clinical practice. METHODS: PegBase was an international, prospective, observational study in which 4441 patients with CHC were enrolled in 27 countries. This analysis focuses on results in 4100 treatment-naïve and previously treated patients treated with PI-based triple therapy or dual therapy, according to the discretion of the investigator and local standards of practice. The primary efficacy outcome was sustained virological response after 12-week follow up (SVR12). RESULTS: SVR12 rates in treatment-naïve genotype (G) 1 patients were 56.6% and 62.9% for recipients of boceprevir plus peginterferon alfa-2a/ribavirin and boceprevir plus peginterferon alfa-2b/ribavirin, respectively, and 65.3% and 58.6% for recipients of telaprevir plus peginterferon alfa-2a/ribavirin and telaprevir plus peginterferon alfa-2b/ribavirin, respectively. In previously treated patients assigned to these four regimens, SVR12 rates were 43.6%, 48.3%, 60.3% and 56.1%, respectively. Among treatment-naïve patients assigned to peginterferon alfa-2a/ribavirin and peginterferon alfa-2b/ribavirin, respectively, SVR12 rates were 49.2% and 41.9% in G1 patients, 75.7% and 83.3% in G2 patients, 65.9% and 65.9% in G3 patients, and 49.7%, and 51.1% in G4 patients. The safety and tolerability of dual and triple therapy were consistent with previous reports. CONCLUSION: The efficacy and safety of first-generation PI-based triple-therapy and dual-therapy regimens in this real-world cohort were broadly comparable to those of previous studies. | en_US |
dc.description.sponsorship | F. Hoffmann-La Roche Ltd., Basel, Switzerland | en_US |
dc.format.extent | 327 - 343 | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Ann Gastroenterol | en_US |
dc.rights | This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
dc.subject | Boceprevir | en_US |
dc.subject | peginterferon | en_US |
dc.subject | ribavirin | en_US |
dc.subject | telaprevir | en_US |
dc.subject | virological response | en_US |
dc.title | Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. | en_US |
dc.type | Article | |
dc.rights.holder | © Hellenic Society of Gastroenterology | |
dc.identifier.doi | 10.20524/aog.2017.0136 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/28469364 | en_US |
pubs.issue | 3 | en_US |
pubs.notes | No embargo | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 30 | en_US |
dcterms.dateAccepted | 2017-02-19 | en_US |